Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ablynx
Deal signed to develop nanobodies for CNS disorders
June 22nd, 2005
Ablynx, developer of nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments, announced that it has signed a collaborative research, development and license agreement with the Ottawa-based National Research Council of Canada (NRC) Institute for Biological Sciences (IBS). This collaboration will make an important contribution to Ablynx's discovery efforts in the area of neurodegenerative diseases. NRC researchers have identified a class of Nanobodies that, unlike many other drugs or conventional antibodies, cross the blood-brain barrier (BBB) in a selective and efficient manner. Ablynx will now collaborate on...
Source: Physician Law Weekly (2005-06-22)
|
